In mice, inhibition of RIPK1 activity effectively reverses disease symptoms and behavioral changes, suggesting that over-activation of RIPK1 is a key factor in the pathogenesis of and a potential therapeutic target against ALS and FTD (Xu et al., 2018b). This evidence concerns the gene RIPK1 and amyotrophic lateral sclerosis.